Combination of PARP and KRASG12D Inhibitors Enhances Therapeutic Efficacy by Exploiting Vulnerabilities(scRNA)

Combination of PARP and KRAS G12D Inhibitors Enhances Efficacy Therapeutic Vulnerabilities in PDAC Overall design: For the subcutaneous KPC1199 tumor models, treatment was initiated when tumors reached an average volume of 80–200 mm3. For the treatment group, Olaparib was intraperitoneally injected daily with a dose of 50 mg/kg, and MRTX1133 was intraperitoneally injected daily with a dose of 30 mg/kg.